Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia

J Am Coll Cardiol. 2021 Jul 13;78(2):193-195. doi: 10.1016/j.jacc.2021.04.091.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiopoietin-Like Protein 3 / antagonists & inhibitors*
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / drug therapy*

Substances

  • ANGPTL3 protein, human
  • Angiopoietin-Like Protein 3
  • Antibodies, Monoclonal
  • evinacumab